...programAstellas Pharma Inc. (Tokyo:4503) discontinued its TIGIT antagonist ASP8374 (PTZ-201) that it gained after acquiring Potenza Therapeutics Inc....

...platform developer Xyphos Biosciences Inc. for $120 million and exercised an option to take out Potenza Therapeutics Inc....

...pipeline since then. It gained two Phase I programs through its December 2018 acquisition of Potenza Therapeutics Inc....

...who is also an executive partner at MPM, previously served as president and CEO of Potenza Therapeutics Inc....

...exercised an exclusive option under an April 2015 deal and acquired Potenza Therapeutics Inc. (Cambridge, Mass.) (see "Potenza Therapeutics...
...Potenza Therapeutics Inc., Cambridge, Mass. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Shannon Lehnbeuter ASP8374, PTZ-201 GITR agonist PTZ-329 Astellas Pharma Inc. Potenza Therapeutics Inc. Neuropilin...

...Pharmaceuticals Inc. (NASDAQ:OMED) has OMP-313M32 in Phase I testing; and Astellas Pharma Inc. (Tokyo:4503) and Potenza Therapeutics Inc....

...products containing the sequence. Trieza is a start-up formed last quarter as a spinout from Potenza Therapeutics Inc....

...The build-to-buys include Mitobridge Inc. , which develops therapeutics that affect mitochondrial function, immuno-oncology play Potenza Therapeutics Inc....

...new fund. They include encapsulated cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.); cancer plays Potenza Therapeutics Inc....

...Astellas also has a build-to-buy deal with a portfolio company from BioVentures 2014, immuno-oncology play Potenza Therapeutics Inc....